XML 50 R41.htm IDEA: XBRL DOCUMENT
v3.23.2

Business Combinations (Details Narrative) - USD ($) $ in Millions |  |  | 6 Months Ended |  |
--- | --- | --- | --- | --- | ---
Feb. 08, 2023 | Apr. 15, 2021 | Jun. 30, 2023 | Dec. 15, 2022 | Dec. 31, 2019
Business Acquisition [Line Items] |  |  |  |  |
Fair value |  |  | $ 2.5 |  |
Chronix Biomedical Inc [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Net deferred tax liabilities |  |  | 2.2 |  |
Goodwill |  |  | 9.5 |  |
Oncocyte Corp [Member] | Development Agreement [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Outstanding equity |  |  |  |  | 25.00%
Oncocyte Corp [Member] | Sublicense Agreement [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Outstanding equity |  |  |  |  | 25.00%
Razor Genomics, Inc. [Member] | Development Agreement [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Clinical trial expense reserve amount |  |  | 4.0 |  |
Razor Genomics, Inc. [Member] | Oncocyte Corp [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Outstanding equity |  |  |  | 70.00% |
Chronix Biomedical Inc [Member] | Merger Agreement [Member] | Maximum [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Business combination consideration transferred |  | $ 14.0 |  |  |
Earnout percentage on collections for sales |  | 15.00% |  |  |
Earnout percentage on collections for sale or license |  | 75.00% |  |  |
Chronix Equity [Member] | Merger Agreement [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Earnout percentage on collections for sales | 10.00% |  |  |  |
Gross proceeds percentage | 5.00% |  |  |  |
Chronix Milestone [Member] | Merger Agreement [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Royalty payments | 15.00% |  |  |  |
Chronix [Member] |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |
Fair value |  |  | $ 14.0 |  |

X
- Definition Clinical trial expense reserve amount. + References No definition available. + Details
Name: | OCX_ClinicalTrialExpenseReserveAmount
Namespace Prefix: | OCX_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Earnout percentage on collections for sale. + References No definition available. + Details
Name: | OCX_EarnoutPercentageOnCollectionsForSale
Namespace Prefix: | OCX_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Earnout percentage on collections for sale or license. + References No definition available. + Details
Name: | OCX_EarnoutPercentageOnCollectionsForSaleOrLicense
Namespace Prefix: | OCX_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Earnout percentage on collections for sales. + References No definition available. + Details
Name: | OCX_EarnoutPercentageOnCollectionsForSales
Namespace Prefix: | OCX_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value of contingent consideration. + References No definition available. + Details
Name: | OCX_FairValueOfContingentConsideration
Namespace Prefix: | OCX_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Royalty payments percentage. + References No definition available. + Details
Name: | OCX_RoyaltyPaymentsPercentage
Namespace Prefix: | OCX_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5 + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 8 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 30 -Paragraph 7 -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6 + Details
Name: | us-gaap_DeferredTaxLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=OCX_ChronixBiomedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=OCX_OncocyteCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=OCX_DevelopmentAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=OCX_SublicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=OCX_RazorGenomicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=OCX_ChronixBiomedicalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=OCX_MergerAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=OCX_ChronixEquityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=OCX_ChronixMilestoneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=OCX_ChronixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |